Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity.

@article{Ritchie2006DrugTA,
  title={Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity.},
  author={Marylyn DeRiggi Ritchie and David W. Haas and Alison A. Motsinger and John P. Donahue and Huso Erdem and Stephen R Raffanti and Peter Rebeiro and Alfred L. George and Richard B Kim and Jonathan L. Haines and Timothy R. Sterling},
  journal={Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
  year={2006},
  volume={43 6},
  pages={779-82}
}
This nested case-control study examined relationships between MDR1, CYP2B6, and CYP3A4 variants and hepatotoxicity during antiretroviral therapy with either efavirenz- or nevirapine-containing regimens. Decreased risk of hepatotoxicity was associated with MDR1 3435C-->T (odds ratio, 0.254; P=.021). An interaction between MDR1 and hepatitis B surface antigen… CONTINUE READING